Status:

TERMINATED

Profile of Soluble and Cellular Biomarkers and of Functional Imaging During Antiangiogenic Therapies in Cancer Patients

Lead Sponsor:

Medical University Innsbruck

Conditions:

Hepatocellular Cancer

Non-small Cell Lung Cancer

Eligibility:

All Genders

18+ years

Brief Summary

Tumour angiogenesis has been identified to play a critical role in tumour growth and this knowledge has led to the identification of new targets for cancer therapy. Multiple angiogenic factors are inv...

Eligibility Criteria

Inclusion

  • Age over 18 years
  • Patients with HCC, NSCLC, RCC or CRC treated with an approved antiangiogenic drug (bevacizumab, sorafenib, sunitinib)\*
  • Patients with at least one measurable lesion. Lesions must be measurable by CT-scan or MRI (Magnetic resonance imaging) according to Response Evaluation Criteria in Solid Tumours (RECIST)

Exclusion

  • Pregnant or breast-feeding patients. Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start of treatment. Both men and women enrolled in this trial must use adequate birth control measures during the course of the trial. The definition of effective contraception will be based on the judgment of the principal investigator or a designated associate.
  • Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results
  • Known or suspected allergy to the investigational agent or any agent given in association with this trial -\_\> allergy
  • MRI contraindications: implants (pacemaker)

Key Trial Info

Start Date :

July 1 2009

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

October 1 2014

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT01507740

Start Date

July 1 2009

End Date

October 1 2014

Last Update

April 29 2015

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University Hospital Innsbruck, Internal Medicine V, Hematology Oncology

Innsbruck, Austria, A-6020